This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

开始日期2024-02-28

申办/合作机构

Elevation Oncology, Inc.

NCT03241810 / Terminated临床2期

Randomized Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer (Merrimack Pharmaceuticals Inc.)

This study is a multi-center, randomized, double-blind, placebo-controlled, Phase 2 study in postmenopausal women with heregulin positive, hormone receptor positive, HER2 negative metastatic, unresectable breast cancer.

开始日期2017-08-15

申办/合作机构

Elevation Oncology, Inc.

NCT02538627 / Terminated临床1期

A Phase 1 Multi Arm Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 With Seribantumab (MM-121), Istiratumab (MM-141), or Trametinib in Biomarker-selected Cancer Patients

This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.

开始日期2015-08-01

申办/合作机构

Merrimack Pharmaceuticals, Inc.

100 项与 Seribantumab 相关的临床结果

登录后查看更多信息

100 项与 Seribantumab 相关的转化医学

登录后查看更多信息

100 项与 Seribantumab 相关的专利（医药）

登录后查看更多信息

项与 Seribantumab 相关的文献（医药）

2024-11-05·Circulation

ErbB3 Governs Endothelial Dysfunction in Hypoxia-Induced Pulmonary Hypertension

Article

作者: Zhang, Junting ; Chen, Yuan ; Li, Yiying ; Yang, Xusheng ; Chen, Rongchang ; Deng, Lin ; Nie, Xiaowei ; Bian, Jin-Song ; Tan, Jianxin ; Chen, Jingyu

BACKGROUND::

Pulmonary hypertension, characterized by vascular remodeling, currently lacks curative therapeutic options. The dysfunction of pulmonary artery endothelial cells plays a pivotal role in the initiation and progression of pulmonary hypertension (PH). ErbB3 (human epidermal growth factor receptor 3), also recognized as HER3, is a member of the ErbB family of receptor tyrosine kinases.

METHODS::

Microarray, immunofluorescence, and Western blotting analyses were conducted to investigate the pathological role of ErbB3. Blood samples were collected for biomarker examination from healthy donors or patients with hypoxic PH. The pathological functions of ErbB3 were further validated in rodents subjected to chronic hypoxia- and Sugen-induced PH, with or without adeno-associated virus-mediated ErbB3 overexpression, systemic deletion, or endothelial cell–specific ErbB3 knockdown. Primary human pulmonary artery endothelial cells and pulmonary artery smooth muscle cells were used to elucidate the underlying mechanisms.

RESULTS::

ErbB3 exhibited significant upregulation in the serum, lungs, distal pulmonary arteries, and pulmonary artery endothelial cells isolated from patients with PH compared with those from healthy donors. ErbB3 overexpression stimulated hypoxia-induced endothelial cell proliferation, exacerbated pulmonary artery remodeling, elevated systolic pressure in the right ventricle, and promoted right ventricular hypertrophy in murine models of PH. Conversely, systemic deletion or endothelial cell–specific knockout of ErbB3 yielded opposite effects. Coimmunoprecipitation and proteomic analysis identified YB-1 (Y-box binding protein 1) as a downstream target of ErbB3. ErbB3 induced nuclear translocation of YB-1 and subsequently promoted hypoxia-inducible factor 1/2α transcription. A positive loop involving ErbB3-periostin-hypoxia–inducible factor 1/2α was identified to mediate the progressive development of this disease. MM-121, a human anti-ErbB3 monoclonal antibody, exhibited both preventive and therapeutic effects against hypoxia-induced PH.

CONCLUSIONS::

Our study reveals, for the first time, that ErbB3 serves as a novel biomarker and a promising target for the treatment of PH.

2024-01-01·Current medicinal chemistry

The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study

Article

作者: Ding, Ke ; Zhang, Jinwei ; Trinder, Amelia

HER3 (Human Epidermal Growth Factor Receptor 3) is frequently overexpressed in various cancers, including non-small cell lung cancer (NSCLC), with a prevalence of 83% in primary tumors. Its involvement in tumorigenesis and resistance to targeted therapies makes HER3 a promising target for cancer treatment. Despite being initially considered “undruggable” due to its lack of catalytic activity, significant progress has been made in the development of anti-HER3 therapeutics. Monoclonal antibodies such as lumretuzumab, seribantumab, and patritumab have shown potential in targeting HER3 to overcome resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Additionally, antibody-drug conjugates (ADCs) like HER3-DXd (patritumab deruxtecan) are new drug candidates that have demonstrated selective delivery of cytotoxic chemicals to NSCLC cells by exploiting HER3's widespread expression, minimizing cytotoxicity. This review aims to evaluate the efficacy of current HER3 therapeutics in development and their therapeutic potential in NSCLC, incorporating evidence from clinical trials.

2022-11-01·JCO precision oncology

Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion

Article

作者: Thavaneswaran, Subotheni ; Deegan, Maegan ; Chan, Wei Yen ; Jansen, Valerie M. ; Grady, John P. ; Thomas, David M. ; Asghari, Ray

项与 Seribantumab 相关的新闻（医药）

2024-12-12

·PRNewswire

Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload – -- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin E™ linker-payload -- – Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and to file an IND application in 2026 – BOSTON, Dec. 12, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the nomination of EO-1022 as its HER3 ADC development candidate. EO-1022 is currently progressing through preclinical development, and Elevation Oncology expects to file an investigational new drug (IND) application in 2026. HER3 is a protein expressed across several types of solid tumors, including breast cancer, EGFR-mutant non-small cell lung cancer and pancreatic cancer, and often associated with poor clinical outcomes. EO-1022 is a differentiated ADC containing seribantumab, an anti-HER3 monoclonal antibody (mAb), and a monomethyl auristatin E (MMAE) payload, with site-specific conjugation to the glycan. EO-1022 is being developed for the treatment of patients living with solid tumors that express HER3. "The nomination of our HER3-ADC development candidate marks a key milestone for Elevation Oncology in bolstering our ADC pipeline. EO-1022 combines the seribantumab antibody and state-of the-art ADC site-specific technology. We believe seribantumab is ideally-suited to be used in an ADC due to its selectivity in delivering cytotoxic payload to HER3-expressing cancer cells and its well-tolerated safety profile demonstrated in over 900 patients in multiple studies," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology. "This program is another step forward in leveraging our ADC and oncology drug development expertise to develop innovative, selective cancer therapies that address significant unmet needs. We look forward to sharing preclinical data for EO-1022 in the first half of 2025, as we continue to advance this asset toward the clinic." Also today, Elevation Oncology announced that it has entered into a licensing agreement with Synaffix B.V. (Synaffix). This licensing agreement gives Elevation Oncology global access to Synaffix's clinical stage, site-specific ADC technology platform, including GlycoConnect® antibody conjugation technology, HydraSpace® polar spacer technology, as well as the toxSYN® linker-payload, SYNstatin E™. The license granted to GlycoConnect® and HydraSpace® technologies is exclusive to HER3 as a single target in combination with SYNstatin E® linker-payload. "HER3 is broadly expressed in various cancer types, making it a compelling target for innovative therapeutic strategies. We believe an ADC approach is uniquely positioned to fully unlock the clinical potential of HER3," said David Dornan, Ph.D., Chief Scientific Officer of Elevation Oncology. "We are excited to nominate EO-1022, which leverages Synaffix's state-of-the art site-specific conjugation and differentiated linker-payload for a potentially best-in-class profile. We look forward to advancing our pipeline, as we work towards transforming the care and treatment of patients living with solid tumors that overexpress HER3." "As a dedicated partner in the ADC space, Synaffix is excited to collaborate with Elevation Oncology to push the boundary of ADC innovation," said Peter van de Sande, Head of Synaffix. "With our state-of-the-art ADC technology platform and established supply chain, Elevation is well-positioned to accelerate the development of its differentiated HER3 ADC." About Elevation Oncology, Inc. Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our ADC expertise to advance a novel pipeline, initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3. Our lead candidate, EO-3021, is a potential best-in-class, Claudin 18.2 ADC and is currently being evaluated in the dose expansion portion of a Phase 1 trial (NCT05980416) in patients with advanced, unresectable or metastatic gastric/gastroesophageal adenocarcinoma that express Claudin 18.2. We are also advancing EO-1022, a HER3-targeting ADC for the treatment of patients living with solid tumors that express HER3, through preclinical development. For more information, visit . About Synaffix Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect®, HydraSpace® and toxSYN® technologies, that together enable any company with an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix. The Synaffix platform enables a rapid timeline to clinic due to the established supply chain of technology components. Synaffix holds granted patents to its technology. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen (acquired by Lepu Biopharma), Innovent Biologics, Kyowa Kirin, Genmab, Macrogenics, Amgen, Hummingbird Biosciences, Chong Kun Dang Pharma, ABL Bio, SOTIO Biotech, Kivu Bioscience, BigHat Biosciences, Illumina and Elevation Oncology. Synaffix was fully acquired by Lonza (SIX:LONN) in June 2023. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical development activities, expected timing of announcements of preclinical results, potential benefits of Elevation Oncology's product candidates, potential market opportunities for Elevation Oncology's product candidates and the ability of Elevation Oncology's product candidates to treat their targeted indications. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "possible," "potential," "will," "would," and other words and terms of similar meaning. Although Elevation Oncology believes that the expectations reflected in such forward-looking statements are reasonable, Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Elevation Oncology's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Elevation Oncology's ability to advance its product candidates, the timing and results of preclinical studies and clinical trials, approvals and commercialization of product candidates, the receipt and timing of potential regulatory designations, Elevation Oncology's ability to fund development activities and achieve development goals, Elevation Oncology's ability to protect intellectual property, Elevation Oncology's ability to establish and maintain collaborations with third parties, and other risks and uncertainties described under the heading "Risk Factors" in documents Elevation Oncology files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Elevation Oncology undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Elevation Oncology Investor and Media Contact Gracie Tong Senior Director, Investor Relations and Corporate Communications [email protected] SOURCE Elevation Oncology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

引进/卖出临床1期并购抗体药物偶联物

2024-04-08

·BioSpace

Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024

-- On-track to nominate development candidate in 2024 -- BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program. The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California. "We are pleased to share the first preclinical proof-of-concept data for our HER3-ADC program, reinforcing our commitment to advancing a portfolio of differentiated ADC-based therapies that may deliver better outcomes for patients," said David Dornan, Ph.D., Chief Scientific Officer of Elevation Oncology. "With our HER3-ADC program, we set out to design a differentiated ADC which selectively binds to HER3 and is internalized to potentially attack HER3-expressing cancerous cells while minimizing systemic exposure. Preclinical data with our proof-of-concept HER3-ADC shows HER3-dependent cell killing and robust anti-tumor activity in vivo where HER3 is expressed at high levels. We look forward to nominating a development candidate from our HER3 program later this year and, subsequently, advancing our program closer to the clinic." HER3 is a clinically validated oncology and antibody-drug conjugate (ADC) target, which is overexpressed in a range of solid tumors, including breast cancer, EGFR-mutant non-small cell lung cancer and pancreatic cancer, and is often associated with poor clinical outcomes. Elevation Oncology's HER3-ADC program conjugated seribantumab, its anti-HER3 monoclonal antibody, with a cleavable valine-citrulline linker and monomethyl auristatin E (MMAE) payload to yield HER3-ADC1, a proof-of-concept molecule with an average drug-antibody ratio (DAR) of 4. In a poster titled, "Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers," Elevation Oncology scientists presented in vitro and in vivo data of a seribantumab-based ADC for patients with HER3-expressing cancers. The data showed: HER3-ADC1 binding to cancer cells, endocytosis, MMAE release and inhibition of proliferation were dependent on HER3 expression. In cytotoxicity assays, HER3-ADC1 displayed HER3-dependent cell killing and outperformed a benchmark HER3-ADC with a deruxtecan payload, which is currently in clinical development. In a patient derived xenograft (PDX) model of pancreatic cancer with high HER3 expression, HER3-ADC1 induced tumor regression, whereas an isotype-MMAE control and a benchmark HER3-ADC with a deruxtecan payload had only a modest effect. The poster presentation is now available in the "Publications" section of Elevation Oncology's website: . About Elevation Oncology, Inc. Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our antibody-drug conjugate (ADC) expertise to advance a novel pipeline, initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3. Our lead candidate, EO-3021, is a potential best-in-class ADC designed to target Claudin 18.2 and is currently being evaluated in a Phase 1 trial (NCT05980416) in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers. Additionally, we expect to nominate a development candidate for our second program, a HER3-targeting ADC for the treatment of patients with solid tumors that overexpress HER3, in 2024. For more information, visit . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated clinical and preclinical development activities, expected timing of announcements regarding development activities, potential benefits of Elevation Oncology's product candidates, potential market opportunities for Elevation Oncology's product candidates and the ability of Elevation Oncology's product candidates to treat their targeted indications. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "possible," "potential," "will," "would," and other words and terms of similar meaning. Although Elevation Oncology believes that the expectations reflected in such forward-looking statements are reasonable, Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Elevation Oncology's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Elevation Oncology's ability to advance its product candidates, the timing and results of preclinical studies and clinical trials, approvals and commercialization of product candidates, the receipt and timing of potential regulatory designations, Elevation Oncology's ability to fund development activities and achieve development goals, Elevation Oncology's ability to protect intellectual property, Elevation Oncology's ability to establish and maintain collaborations with third parties, and other risks and uncertainties described under the heading "Risk Factors" in documents Elevation Oncology files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Elevation Oncology undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Elevation Oncology Investor and Media Contact Candice Masse, 978-879-7273 Senior Director, Corporate Communications & Investor Relations cmasse@elevationoncology.com Company Codes: NASDAQ-NMS:ELEV

临床1期抗体药物偶联物AACR会议

2024-02-14

·Firstwordpharma

Merrimack to close out and cash in after $225M milestone

Hours after becoming eligible for a hefty milestone payment, Merrimack Pharmaceuticals announced plans on Tuesday to dissolve the company and distribute the windfall among shareholders. Merrimack is set to receive $225 million from Ipsen after the FDA approved a four-drug regimen featuring Onivyde (irinotecan liposome injection) to treat first-line metastatic pancreatic adenocarcinoma. Ipsen acquired US rights to Onivyde from Merrimack in 2017. For more, see ViewPoints: Ipsen success provides epitaph for Merrimack.The only other licensing deal Merrimack has is with Elevation Oncology, which has rights to anti-HER3 antibody seribantumab under a 2019 deal. However, Elevation paused development of the experimental cancer treatment last year until it could find a partner.Given that Merrimack doesn’t expect to receive any additional milestone payments, the company plans to shutter operations and pay investors a cash dividend between $14.65 and $15.35 per share, pending a shareholder meeting scheduled for May. Shares in Merrimack ticked down 2% on Wednesday to close at $14.67. Merrimack is the second company this week to close shop and cash out. LianBio said Tuesday it plans to wind down operations, sell its remaining pipeline assets, and pay investors a cash dividend of $4.80 per share. The move comes just months after the company pocketed $350 million from selling off certain Asia rights for cardiac myosin inhibitor mavacamten to Bristol Myers Squibb.

引进/卖出上市批准临床3期并购

100 项与 Seribantumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11777	Seribantumab	-	DB11857

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胆管癌	临床2期	美国	Elevation Oncology, Inc.	2024-02-28
胆管癌	临床2期	澳大利亚	Elevation Oncology, Inc.	2024-02-28
胆管癌	临床2期	加拿大	Elevation Oncology, Inc.	2024-02-28
胆管癌	临床2期	韩国	Elevation Oncology, Inc.	2024-02-28
膀胱癌	临床2期	美国	Elevation Oncology, Inc.	2024-02-28
膀胱癌	临床2期	澳大利亚	Elevation Oncology, Inc.	2024-02-28
膀胱癌	临床2期	加拿大	Elevation Oncology, Inc.	2024-02-28
膀胱癌	临床2期	韩国	Elevation Oncology, Inc.	2024-02-28
乳腺癌	临床2期	澳大利亚	Elevation Oncology, Inc.	2024-02-28
乳腺癌	临床2期	韩国	Elevation Oncology, Inc.	2024-02-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCLC2024	N/A	NRG1融合阳性非小细胞肺癌	-	Seribantumab	網廠壓鬱製膚糧顧鹽積(壓鏇鏇網製簾壓顧齋築) = 窪齋餘鑰繭鏇積窪觸網製壓築觸憲廠築積夢繭 (繭鏇構齋繭壓壓齋觸築 )	-	2024-09-09
NCT04383210 (CRESTONE, AACR2023) 人工标引	临床2期	实体瘤二线 NRG1 Expression	51	seribantumab 3g	窪夢觸繭鹽鹹遞選淵顧(廠膚壓簾製獵壓蓋鹹鬱) = 壓鏇積鑰鑰夢鬱鑰觸廠獵蓋遞襯鏇衊夢願醖淵 (憲願齋衊簾簾獵餘選衊 ) 更多	积极	2023-04-14
NCT04383210 (CRESTONE, ASCO2022)	临床2期	肉瘤 \| 转移性实体瘤 \| NRG1融合阳性实体瘤 ... 更多	12	Seribantumab 3g QW	製簾壓網鏇鹽繭膚廠襯(鬱艱糧淵衊遞餘淵觸構) = 網鹽構膚憲繭淵糧醖糧繭鑰繭襯製願廠壓構網 (製選觸醖鬱鹽衊構遞顧 )	-	2022-06-02
NCT00734305 (Pubmed) 人工标引	临床1期	实体瘤	44	Seribantumab (dose escalation)	襯窪窪憲遞廠製淵遞齋(襯觸淵鹽鑰鬱鑰選衊夢) = maximum tolerated dose was not reached. 艱壓醖繭遞壓遞網繭餘 (艱簾鹽壓網蓋壓醖夢鏇 ) 更多	积极	2021-12-01
				Seribantumab (dose expansion)
NCT02387216 (SHERLOC, CTgov)	临床2期	腺癌 \| 转移性非小细胞肺癌	153	Docetaxel+MM-121 (Arm A (Experimental): MM-121 in Combination With Docetaxel)	鹹觸簾鏇壓範繭獵鏇簾(餘壓餘鹹蓋鬱襯觸蓋糧) = 鹹壓憲顧餘齋網壓製窪鹹鹽鑰壓選廠窪壓夢襯 (艱遞淵顧膚蓋鑰鹽願鬱, 製網鹽憲衊積願廠範觸 ~ 築衊壓夢窪糧淵窪醖鬱) 更多	-	2021-10-12
				Docetaxel (Arm B (Comparator): Docetaxel Alone)	鹹觸簾鏇壓範繭獵鏇簾(餘壓餘鹹蓋鬱襯觸蓋糧) = 餘蓋範膚憲鬱淵壓窪襯鹹鹽鑰壓選廠窪壓夢襯 (艱遞淵顧膚蓋鑰鹽願鬱, 繭淵構鏇窪憲窪繭觸齋 ~ 夢構積築餘襯構鹹齋鬱) 更多
NCT03241810 (SHERBOC, CTgov)	临床2期	HER2阳性转移性乳腺癌 \| 转移性乳腺癌 \| HR阳性/HER2阴性乳腺癌	22	Fulvestrant+Seribantumab (Arm A (Experimental): Seribantumab and Fulvestrant)	願製齋繭鏇衊齋獵壓築(蓋遞醖鹹顧鑰艱範膚淵) = 選膚範築齋衊餘鏇醖夢範製選衊廠糧積鏇選網 (襯鏇鬱繭遞鏇積築鹽膚, 積鬱構蓋願壓鏇淵膚鹹 ~ 憲窪範製顧簾鬱範衊齋) 更多	-	2020-09-02
				Placebo+Fulvestrant (Arm B (Control): Placebo and Fulvestrant)	願製齋繭鏇衊齋獵壓築(蓋遞醖鹹顧鑰艱範膚淵) = 築鹹鬱製糧簾鹹糧鹹鏇範製選衊廠糧積鏇選網 (襯鏇鬱繭遞鏇積築鹽膚, 鑰餘淵網壓顧觸淵廠憲 ~ 蓋願鹽簾淵餘蓋餘構願) 更多
NCT02387216 (Pubmed \| Oncologist)	临床2期	EGFR突变的非小细胞肺癌	153	Seribantumab + Erlotinib	衊衊願網夢鹹繭蓋鑰鬱(簾齋憲積簾醖繭窪鏇壓) = 糧壓選顧範構選窪構衊遞築糧壓醖淵鏇簾窪鏇 (醖觸簾觸鬱衊簾範築顧 ) 更多	-	2019-08-01
				Erlotinib alone	衊衊願網夢鹹繭蓋鑰鬱(簾齋憲積簾醖繭窪鏇壓) = 鏇膚齋繭壓獵窪積廠糧遞築糧壓醖淵鏇簾窪鏇 (醖觸簾觸鬱衊簾範築顧 ) 更多
NCT02387216 (SHERLOC, ASCO 12019 \| ASCO 22019) 人工标引	临床2期	非小细胞肺癌 HRG positive	108	docetaxel 75 mg+MM-121 3000 mg	餘獵鑰範餘齋鏇餘窪願(壓餘網衊蓋糧繭鑰簾積) = 蓋淵壓廠願鏇築窪窪壓築築襯餘齋簾鹹顧齋範 (淵夢衊鑰憲壓艱積製觸 ) 更多	不佳	2019-06-02
				docetaxel 75 mg	餘獵鑰範餘齋鏇餘窪願(壓餘網衊蓋糧繭鑰簾積) = 齋獵壓糧襯願艱夢壓齋築築襯餘齋簾鹹顧齋範 (淵夢衊鑰憲壓艱積製觸 ) 更多
NCT01447706 (CTgov)	临床2期	腹膜癌 \| 卵巢上皮癌 \| 铂耐药性卵巢癌 ... 更多	223	Paclitaxel	淵壓鬱遞獵蓋淵願繭築(觸顧膚網糧艱窪鑰窪網) = 廠願廠繭壓糧獵構鬱淵願鏇構觸選壓餘壓簾鑰 (膚壓蓋獵鏇顧糧網衊製, 獵憲襯繭築齋窪鑰齋蓋 ~ 鬱膚壓鏇鹽醖觸膚鏇製) 更多	-	2016-05-12
NCT01151046 (CTgov)	临床2期	HER2 阴性乳腺癌	118	Placebo+Exemestane	廠鬱廠鑰鬱獵壓襯構鑰(積壓構襯選鹹繭壓餘願) = 獵鑰艱膚襯蓋鬱夢艱願淵鑰憲窪餘構繭鹹構夢 (簾夢膚憲繭廠廠窪醖艱, 糧齋選膚鹹醖壓鹹顧繭 ~ 顧遞醖製壓憲壓鬱範夢) 更多	-	2016-05-12